Introduction
The programmed cell death 4 (Pdcd4) gene encodes a multi-functional nuclear-cytoplasmic shuttling protein that is involved in the regulation of transcription and translation and functions as a tumor suppressor (for recent review see Lankat-Buttgereit and Go¨ke, 2009 ). Pdcd4 is highly conserved among vertebrates with homologs found also in distantly related species, such as Drosophila melanogaster, the sponge Suberites domuncula and even plants (http://pfam.sanger.ac.uk/). Pdcd4 contains two so-called MA-3 domains in the central and C-terminal parts of the protein, which mediate protein-protein interactions, and an N-terminal RNA-binding domain. Pdcd4 was originally identified as a gene whose expression is increased during apoptosis (Shibahara et al., 1995) , but has now been implicated as a tumor suppressor in a broad spectrum of human tumors. Pdcd4 was initially shown to suppress tumor development in an in vitro mouse keratinocyte model of tumor promotion (Cmarik et al., 1999) . More recently, decreased expression of Pdcd4 has been implicated in the development and progression of human lung, colon, liver and breast cancer (Chen et al, 2003; Afonja et al, 2004; Zhang et al., 2006; Mudduluru et al., 2007) . Pdcd4 expression is controlled by multiple mechanisms. Pdcd4 mRNA is targeted by microRNA miR-21, whose overexpression in cancer cells downregulates Pdcd4 expression (Asangani et al., 2008; Lu et al., 2008) . On the protein level, p70(S6K) kinase-mediated phosphorylation of Pdcd4 triggers its ubiquitinylation by the E3 ubiquitin ligase complex SCF(betaTRCP) and its subsequent degradation (Dorello et al., 2006) . Recent work has suggested that downregulation of Pdcd4 expression contributes to tumor development by stimulating the mobility and metastatic potential of tumor cells Asangani et al., 2008) , and by deregulating the cellular DNA damage response (Bitomsky et al., 2008; Singh et al., 2009 ).
Pdcd4 has emerged as an important regulator of both transcription and translation. Pdcd4 affects transcription of certain genes by modulating the activities of specific transcription factors, such as c-Jun (Yang et al., 2003b; Bitomsky et al., 2004) , Sp1 and p53 (Bitomsky et al., 2008) . As a translation regulator, Pdcd4 interacts with the eukaryotic translation initiation factor eIF4A, a RNA helicase that catalyzes the unwinding of mRNA secondary structures in 5 0 -untranslated regions (UTRs) (Yang et al., 2003a (Yang et al., , 2004 . Binding of Pdcd4 to eIF4A is mediated by the MA-3 domains, whose structure and complex formation with eIF4A have been analyzed in detail (LaRondeLeBlanc et al., 2007; Waters et al., 2007 Waters et al., , 2011 Suzuki et al., 2008; Chang et al., 2009; Loh et al., 2009) . Because binding of Pdcd4 to eIF4A inhibits the helicase activity of eIF4A (Yang et al., 2003a; Yang et al, 2004) , it is believed that Pdcd4 functions as a suppressor of cap-dependent translation of mRNAs with structured 5 0 -UTRs. This assumption was supported by studies, which assessed the effects of Pdcd4 on the translation of artificial RNAs containing 5 0 -hairpin structures (Yang et al., 2003a (Yang et al., , 2004 ; however, because physiological translational target mRNAs for Pdcd4 have not yet been unambiguously identified, it is presently unclear whether translation of all RNAs containing structured 5 0 -UTRs are suppressed by Pdcd4 or whether there are mechanisms that allow Pdcd4 to target specific mRNAs.
In this study, we report the identification of protooncogene c-myb mRNA as the first physiological target RNA of Pdcd4. We show that Pdcd4 is associated with c-myb mRNA and suppresses its translation. The inhibitory effect of Pdcd4 is mediated by sequences located within the c-myb-coding region. We demonstrate that the Pdcd4 RNA-binding domain has a key role in targeting Pdcd4 to c-myb mRNA by mediating preferential binding of Pdcd4 to RNA secondary structure formed by the response region in c-myb mRNA. In summary, our work demonstrates for the first time that Pdcd4 is directly involved in translational suppression of a natural mRNA and offers the first insight into how Pdcd4 targets a specific mRNA.
Results

c-myb mRNA is a translational target of Pdcd4
We have previously shown that Pdcd4 inhibits the activity of transcription factors c-Jun and p53 by interfering with their ability to cooperate with p300 (Bitomsky et al., 2004 (Bitomsky et al., , 2008 . While studying the effect of Pdcd4 on c-Myb, another transcription factor recruiting p300, we noted that Pdcd4 strongly decreased the amount of c-Myb generated from a cytomegalovirus (CMV) promoter-based c-Myb expression vector. The inhibitory activity of Pdcd4 was specific, because the amounts of b-galactosidase, C/EBPb or green fluorescent protein (GFP) derived from similar CMV promoter-based expression vectors were not affected. The inhibitory activity was shared by avian and human Pdcd4 (Figure 1a) , and was also observed when expression vectors for mouse or human c-Myb were used (data not shown), indicating that it was a conserved feature of Pdcd4 and c-Myb. The reduced expression of c-Myb was not accompanied by lower steady-state levels (a) QT6 fibroblasts were transfected with plasmids encoding chicken c-Myb (2 mg), chicken C/EBPb (2 mg), EGFP (2 mg) and human or chicken Pdcd4 (2 and 5 mg). Total protein extracts were analyzed by western blotting with antibodies against c-Myb, C/EBPb or GFP. (b) Cells were transfected with expression vectors for c-Myb and human Pdcd4. Polyadenylated RNA was analyzed by northern blotting using myb and gapdh probes (top) or by western blotting for the expression of c-Myb (bottom). (c) QT6 cells transfected as in (b) were fractionated into nuclear (N) and cytoplasmic (C) fractions, and RNA isolated from both fractions was analyzed by northern blotting using myb and gapdh probes. (d) QT6 cells transfected as in (b) were treated with 10 mM MG132 for 5 h or were left untreated. Cells were analyzed by western blotting as in (b) . (e) QT6 cells were transfected as in (a). Cytoplasmic extracts were sedimented through 10-50 % sucrose density gradients. Aliquots of the gradient fractions were analyzed by agarose gel electrophoresis for the distribution of ribosomal RNAs (top). Subsequently, fractions 1-3 and 4-9 were pooled as non-ribosomal (pool A) and ribosomal fractions (pool B), respectively. RNA isolated from these fractions was then analyzed by quantitative real-time PCR for c-myb (black columns) and b-galactosidase (gray columns) mRNAs. The columns show the amounts of both RNAs in the ribosomal compared with the non-ribosomal fractions. The amounts present in the non-ribosomal factions were normalized to 1. The asterisk indicates statistical significance (Po0.005; Student's-t test).
or altered nuclear-cytoplasmic distribution of myb mRNA (Figures 1b and c) , suggesting that Pdcd4 neither affected the transcription or the stability of c-myb mRNA nor its nuclear export. Furthermore, blocking protein degradation by the proteasome inhibitor MG132 did not abolish the inhibitory effect of Pdcd4. This indicated that Pdcd4 did not decrease the amount of c-Myb by stimulating its degradation (Figure 1d ). Taken together, these experiments suggested that Pdcd4 suppresses the translation of c-Myb.
To substantiate this conclusion we subjected cytoplasmic extracts of cells transfected with c-Myb or c-Myb plus Pdcd4 expression vectors to sucrose density gradient centrifugation. We then analyzed the distribution of c-myb mRNA between non-ribosome-containing fractions and mono-or polyribosome-containing fractions. This allowed us to determine whether Pdcd4 affected the amount of c-myb RNA engaged in translation (i.e., associated with ribosomes). Figure 1e shows that the amount of ribosome-associated c-myb RNA was decreased when Pdcd4 was expressed, consistent with the notion that Pdcd4 inhibits the translation of c-myb mRNA. The Pdcd4-dependent decrease of ribosomal association of c-myb RNA was specific, as the distribution of b-galactosidase mRNA, used as internal control, was not affected by Pdcd4.
To assess the effect of Pdcd4 on c-Myb expression under more physiological conditions we made use of a Pdcd4-deficient clone of the chicken DT40 cell line that we had established previously (Singh et al., 2009) . Consistent with the results of Figure 1 , the steady-state level of c-Myb was increased in the Pdcd4 knockout cells (Figure 2a ). Northern blotting showed that this increase was not due to increased transcription of c-myb (Figure 2b) . Treatment of the cells with the proteasome inhibitor MG132 did not abolish the difference of the amount of c-Myb between wild-type and Pdcd4-deficient cells, indicating that this difference was not due to different half-lives of c-Myb in both cells (Figure 2c ). Furthermore, we compared the turnover of c-Myb in the DT40 wildtype and Pdcd4 knockout cells after blocking protein synthesis with cycloheximide to confirm that there was no significant difference in the half-life of the protein in both cells (Figure 2d ). To confirm that the increased expression of c-Myb was caused by the loss of Pdcd4, we re-expressed chicken Pdcd4 in the knockout cells. Figure 2e shows that restoration of Pdcd4 expression reduced the amount of c-Myb in the knockout cells to the level found in wild-type DT40 cells. Taken together, the experiments illustrated in Figures 1 and 2 provide strong evidence that c-myb mRNA is a translational target of Pdcd4. This conclusion was further supported by demonstrating that Pdcd4 also inhibits translation of c-Myb in an in vitro translation system (Supplementary Figure S1) .
We have previously shown that transcription of Pdcd4 is stimulated by v-Myb and c-Myb (Schlichter et al., 2001a, b; Appl and Klempnauer, 2002) . The finding that translation of c-myb mRNA is suppressed by Pdcd4 suggests that the expression of both genes is controlled by an autoregulatory feedback loop, as illustrated in Figure 2f .
Pdcd4 is associated with c-myb mRNA in vivo To investigate whether c-myb mRNA is a direct translational target of Pdcd4 we asked whether Pdcd4 is associated with c-myb mRNA in vivo. To address this question we transfected fibroblasts with combinations of expression vectors for c-Myb, luciferase and Pdcd4, followed by analysis of cytoplasmic extracts by RNA immunoprecipitation (RIP). The cells were treated with formaldehyde to crosslink protein-RNA complexes, and cytoplasmic extracts were then immunoprecipitated Translation suppression by Pdcd4 P Singh et al with antibodies against Pdcd4, followed by reverse transcription of the co-precipitated RNA and PCR analysis. As shown in Figure 3a , c-myb RNA was enriched in the immunoprecipitate derived from Pdcd4 expressing cells. This enrichment was specific because it was not observed when the Pdcd4 expression vector was omitted and because luciferase RNA, which was used as an internal control, was not enriched. This experiment, therefore, demonstrated that Pdcd4 is associated with c-myb RNA in vivo. To confirm the binding of Pdcd4 to c-myb mRNA under physiological conditions we also analyzed DT40 cells by RIP. Figure 3b shows that c-myb RNA was enriched by IP from extracts from DT40 wildtype cells but not from extracts from Pdcd4-deficient cells. This enrichment was specific, as b-actin mRNA, which was analyzed as an internal control, was not enriched. Finally, Pdcd4-deficient cells reconstituted with the Pdcd4 expression vector again showed specific enrichment of c-myb mRNA in a RIP experiment (Figure 3c ). Taken together, these experiments clearly demonstrated that Pdcd4 is associated with c-myb mRNA in vivo.
The c-myb-coding region contains a translational 'Pdcd4-response element' The finding that c-myb RNA is physically associated with Pdcd4 permitted us to investigate how Pdcd4 targets a specific mRNA. Because Pdcd4 suppressed translation of myb RNA transcribed from a CMV promoter-based expression vector containing only the cmyb-coding region, this suggested that the sequences responsible for targeting Pdcd4 to c-myb RNA are located in the coding region of the mRNA. To identify the part of the c-myb mRNA that mediates the inhibitory effect of Pdcd4, we first generated 3 0 -deletions of the c-Myb expression vector and examined the effect of Pdcd4 on the steady-state levels of the resulting truncated proteins. As illustrated in Figure 4b , truncation of 3 0 of the coding region up to a BglII or a SalI site, leading to the expression of truncated c-Myb proteins containing amino acids 1-497 and 1-303, respectively, did not significantly affect the ability of Pdcd4 to inhibit translation. When the deletion of coding sequences was extended to a NaeI site, translation of the resulting protein (amino acids 1-236) was no longer suppressed by Pdcd4. We therefore concluded that the translational 'Pdcd4-response element' maps to 5 0 -sequences to the SalI site. We also performed RIP experiments using extracts from cells transfected with expression vectors from full-length and truncated cMyb. These experiments showed that the RNA encoding the truncated c-Myb protein, which was no longer suppressed by Pdcd4 (c-Myb DNae), was also not associated with Pdcd4 in vivo (Figure 4d) .
To map the Pdcd4-responsive region from the 5 0 -end of c-myb mRNA, we analyzed N-terminal deletion mutants of c-Myb (Figure 4c ). These experiments showed that c-myb-coding sequences between the 5 0 -end and an XmaI site could be deleted without abrogating the inhibitory effect of Pdcd4. Together with the data illustrated in Figure 4b this showed that the 'Pdcd4-response region' maps to the center of the c-mybcoding region between the XmaI and SalI sites.
Pdcd4 has been shown to suppress cap-dependent initiation of translation by interacting with eIF4A and inhibiting its helicase activity (Yang et al., 2003a (Yang et al., , 2004 ; Translation suppression by Pdcd4 P Singh et al however, because the Pdcd4-responsive region is located within the coding region of c-myb mRNA, we also considered the possibility that Pdcd4 might function by slowing down elongating ribosomes or causing ribosomal drop-off. Ribosomal drop-off has been implicated in the translational inhibition caused by microRNAs that target the coding region of certain mRNAs (Nottrott et al., 2006; Petersen et al., 2006) . To explore this possibility we constructed a bicistronic expression vector in which the c-myb-coding region is placed downstream of the hepatitis C virus internal ribosomal entry site. If Pdcd4 functions by inhibiting ribosomal elongation, c-Myb expression will still be suppressed by Pdcd4 under these conditions. On the other hand, if Pdcd4 suppresses cap-dependent initiation of translation, c-Myb expression might not be affected because the mechanism of translational initiation at the hepatitis C virus internal ribosomal entry site is distinct from capdependent translation initiation and does not require translation initiation factors (Lancaster et al., 2006 ). The Pdcd4 N-terminal domain is required for suppression of c-myb translation and binds preferentially to the Pdcd4-response region of c-myb mRNA. To understand how Pdcd4 is recruited to c-myb mRNA we investigated the role of the Pdcd4 N-terminal domain in translational suppression of c-myb RNA. Previous work has shown that the amino terminal domain of Pdcd4 binds to RNA and that its RNA-binding activity is mediated by two clusters of basic amino acids. Mutation of both clusters (which are referred to as RBM1 and 2) results in a complete loss of the RNAbinding activity (Bo¨hm et al., 2003; Wedeken et al., 2010) . As shown in Figure 5 , mutant Pdcd4 carrying mutations of the basic amino acid clusters inhibited c-Myb translation less strongly than wild-type Pdcd4, Nco, E, X, N, S and B refer to restriction sites for NcoI, EcoRI, XmaI, NaeI, SalI and BglII, respectively. The hatched region marks the Pdcd4 target region. (b, c) QT6 fibroblasts were transfected with plasmids encoding full-length or truncated versions of c-Myb (2 mg each) and Pdcd4 (2 and 5 mg), as well as with the b-galactosidase expression vector pCMVb (0.5 mg). Cells were harvested after 24 h and the b-galactosidase activity was determined. b-galactosidase-normalized amounts of cell extracts were then analyzed by western blotting with antibodies against c-Myb. (d) QT6 cells were transfected with plasmids encoding full-length or DNae-truncated c-Myb, Pdcd4 and firefly luciferase. Cytoplasmic extracts were subjected to RIP with Pdcd4-specific antibodies. The amounts of c-myb (black columns) and luciferase (white columns) mRNAs present in the immunoprecipitates were determined by quantitative real-time PCR. The amounts of myb and luciferase RNAs present in control precipitate (i.e., from cells transfected without Pdcd4 expression vector) were normalized to 1. (e) QT6 fibroblasts were transfected with the mono-and bicistronic c-Myb expression vectors shown at the top, with or without increasing amounts (2 and 5 mg) of Pdcd4 expression vector. Cell extracts were analyzed by western blotting with antibodies against c-Myb, Pdcd4 or GFP. c-Myb encoded by the bicistronic expression vector has a slightly higher molecular weight because translation is started within the hepatitis C virus internal ribosomal entry site.
Translation suppression by Pdcd4
P Singh et al indicating that RNA binding is required for efficient translational suppression of c-myb mRNA. This suggested that Pdcd4 might target myb RNA by a direct protein-RNA interaction with the 'Pdcd4-response element' in the c-myb-coding region.
To explore this possibility and to substantiate a role of RNA binding in targeting Pdcd4 to c-myb mRNA we prepared GST-Pdcd4 fusion proteins having the wildtype or a mutated RNA-binding domain, and performed RNA electrophoretic mobility shift assays with in vitro synthesized RNAs. As shown in Figure 6a , we generated three overlapping RNAs from the central part of the cmyb mRNA (referred to as c-myb#1, 2 and 3). Upon electrophoresis in native polyacrylamide gels, each of the RNAs gave rise to fast-and slow-migrating forms, the latter of which disappeared upon heat denaturation (Figure 6b ). This indicated that the slower migrating forms are due to the formation of secondary structures. The propensity to form secondary structure was most prominent in case of RNA c-myb#3, which corresponds to the central part of the Pdcd4-response region. We performed RNA secondary structure prediction by Mfold (http://mfold.bioinfo.rpi.edu) to confirm that RNA c-myb#3 is indeed able to form a significant amount of secondary structure (Supplementary Figure S2) . Figure 6d shows that wild-type Pdcd4 bound preferentially to the slower migrating form of RNA c-myb#3, as is evident from the fact that the slow-migrating form of the RNA was efficiently shifted to even slower migrating complexes appearing in the upper part of the gel, whereas the fast-migrating form of the RNA, which lacks secondary structure, remained virtually unbound by Pdcd4, under these conditions. The mutant Pdcd4, used as negative control, did not bind to any of the RNA forms. The RNA bound by Pdcd4 appeared as a continuous smear in the upper part of the gel, suggesting that Pdcd4 does not form stable protein-RNA complexes under the conditions of electrophoresis. To substantiate our conclusion that Pdcd4 binds preferentially to the structured form of the RNA, we also performed additional RNA-binding experiments in which we used unlabeled c-myb#3 RNA as competitor (Figure 6e) . Overall, these experiments confirmed that the structured form of the RNA was much more effective as a competitor when the denatured form of the RNA was used as the radiolabeled probe rather than the native form (compare lanes 3-5 and 8-10 of Figure 6e ). Furthermore, the denatured form of unlabeled c-myb#3 RNA competed less well than the native form of this RNA (compare lanes 8-10 and 11-13 of Figure 6e ). We also compared the binding of Pdcd4 to RNA c-myb#3 and an unrelated RNA (c-myb1-111) derived from the 5 0 -end of c-myb mRNA, which is not involved in Pdcd4-dependent suppression of c-Myb translation (Figure 6f ). This RNA also formed secondary structure, as evidenced by the appearance of fast-and slow-migrating bands and the disappearance of the slow-migrating form after heat denaturation (Figure 6g ). Interestingly, binding of Pdcd4 to the structured form of c-myb#3 was more efficient than binding to the structured form of the RNA from the 5 0 -end of c-Myb, indicating that preferential binding of Pdcd4 is mediated by a specific RNA structural motif formed by the Pdcd4-response region of c-myb mRNA, and not by the formation of secondary structure per se.
We also compared the binding of Pdcd4 to the denatured forms of RNAs c-myb#3 and c-myb1-111. As shown in Figure 6g , there was no significant difference in binding to both denatured RNAs. Taken together, these experiments provide the first evidence that the Pdcd4 RNA-binding domain has an intrinsic preference for binding to an RNA structural motif. The fact that such a motif is formed by that part of c-myb mRNA that is essential for translational suppression of the RNA by Pdcd4 strongly suggests that Pdcd4 is recruited to c-myb mRNA, at least in part, by preferential RNA binding.
Discussion
In this work, we have identified chicken c-myb mRNA as the first physiological and direct translational target of Pdcd4. The amount of c-Myb protein generated from a transfected c-Myb expression vector is significantly decreased by Pdcd4. We have shown that this decrease is not due to decreased transcription, altered nuclear export of the mRNA or effects of Pdcd4 on c-Myb protein stability. Rather, we have demonstrated that the association of c-myb mRNA with ribosomes is decreased by Pdcd4. Importantly, by using Pdcd4 knockout cells, we have confirmed that Pdcd4 affects c-myb mRNA translation also in non-transfected cells not overexpressing Pdcd4. Finally, we have demonstrated that Pdcd4 is physically associated with c-myb mRNA in vivo. Altogether, these data provide compelling evidence that c-myb mRNA is a direct translational target of Pdcd4. We have previously shown that c-Myb directly activates transcription of the Pdcd4 gene via an array of Myb binding sites in the promoter of the Pdcd4 gene (Schlichter et al., 2001a, b, Appl and Klempnauer, 2002) . The finding that Pdcd4 suppresses the translation Translation suppression by Pdcd4 P Singh et al of c-myb mRNA places c-Myb and Pdcd4 in a regulatory feedback loop in which Pdcd4 restricts cMyb activity by suppressing its synthesis. Such a feedback mechanism might be important to control the proliferation-stimulating activity of c-Myb and would be consistent with Pdcd4's function as a tumor suppressor. This might be relevant, for example, in colon cancer in which downregulation of Pdcd4 expression and increased c-myb expression are frequently associated with highly malignant states (Mudduluru et al., 2007; Ramsay and Gonda, 2008) . The identification of c-myb mRNA as a target of Pdcd4 has allowed, for the first time, to examine how Pdcd4 is targeted to a specific mRNA. Our data indicate that Pdcd4 targets a 'Pdcd4-response element' that maps to the coding region of c-myb mRNA. At first glance, it appears unusual that the coding region of an mRNA is the target of a translational regulatory mechanism; however, genome-wide analyses of interactions of regulatory RNA-binding proteins with mRNAs have revealed surprisingly large numbers of interactions that take place in the coding regions of the cognate mRNAs (Hogan et al., 2008; Hafner et al., 2010) . Previous studies have also identified specific regulatory proteins that bind to the coding regions of certain mRNAs, such as the thymidylate synthase and dihydrofolate reductase, both of which bind to the coding regions of their own mRNAs (Ercikan-Abali et al., 1997; Lin et al., 2000; Zhang et al., 2010) and the RNA-binding protein HuR, which interacts with the coding region of CD83 RNA (Prechtel et al., 2006) . Target sites for microRNAs are also not restricted to the 3 0 -UTRs but can occur in the coding region of certain mRNAs. Such target sites are clearly functional as they have been shown to mediate translational suppression of the respective mRNAs (Nottrott et al., 2006; Petersen et al., 2006) .
Our analysis of the binding of Pdcd4 to c-myb RNA also highlights the role of the Pdcd4 N-terminal domain whose physiological function has not been clarified so far. Initially, in vitro binding experiments using nonspecific RNA suggested that the N-terminal part of Pdcd4 is involved in RNA binding (Bo¨hm et al., 2003) . More recently, we have shown that the Pdcd4 RNAbinding domain is required for the association of Pdcd4 with ribosomal complexes in vivo, providing the first evidence for a role of RNA binding in targeting Pdcd4 to the translation machinery (Wedeken et al., 2010) . The identification of a 'Pdcd4-response region' in c-myb mRNA has allowed, for the first time, to study RNA binding of Pdcd4 in the context of a physiological RNA target site. As a result, our work provides the first evidence that the Pdcd4 RNA-binding domain is able to preferentially recognize specific RNA regions and suggests that RNA binding by Pdcd4 has a key role in targeting of Pdcd4 to specific mRNAs. Interestingly, it appears that not a RNA sequence per se is recognized by Pdcd4 but rather a secondary structure formed by the RNA is recognized.
Overall, our work demonstrates for the first time that Pdcd4 is directly involved in translational suppression of a natural mRNA and offers a framework for how Pdcd4 targets specific mRNAs. It will now be interesting to identify and characterize additional Pdcd4 target mRNAs to further explore this mechanism.
Materials and methods
Cells and transfections
Transient transfections were performed in the QT6 fibroblast line as described (Bitomsky et al., 2008) . To monitor and normalize transfection efficiencies, the b-galactosidase expression plasmid CMVb (Invitrogen, Karlsruhe, Germany) was included in each transfection. DT40 Pdcd4 (À/À) cells and Pdcd4 (À/À) cells re-expressing hemagglutinin-tagged versions of Pdcd4 have been described (Singh et al., 2009) .
Expression vectors
The chicken c-Myb expression vector was obtained by isolating the coding region of full-length c-Myb as a NcoI (partial)/XbaI fragment from pCM100 plasmid (Foos et al., 1992) and inserting it together with an oligonucleotide adapter (GAATTCACCATGG) between the EcoRI and XbaI sites of pCDNA4 (Invitrogen). pCDNA4-chcmyb-DBgl, pCDNA4-chcmyb-DSal and pCDNA4-chcmyb-DNae are derivatives encoding C-terminally truncated proteins containing c-myb amino acids 1-497, 1-303 and 1-236, respectively. pCDNA4-chcmyb-DN93, pCDNA4-chcmyb-DN185 and pCDNA4-chcmyb-ID148 encode N-terminally truncated proteins lacking amino acids 2-95, 2-186 and 81-234, respectively. The bicistronic GFP-HCV-Myb expression vector was generated by first inserting the hepatitis C virus internal ribosomal entry site and the c-myb-coding region into pEGFP-C1 (Clontech, Heidelberg, Germany) downstream of the GFP-coding region. In the resulting plasmid, the HCV translational start codon is linked via a 123 base-pair sequence in-frame to the c-Myb start codon. pCDNA4-CCR encodes full-length chicken C/EBPb (Plachetka et al, 2008) . pCMVluc was obtained by inserting the CMV promoter into pGL3-basic (Promega, Mannheim, Germany). Expression vectors for hemagglutinin-tagged chicken Pdcd4 and wild-type human Pdcd4 have been described (Schlichter et al., 2001a; Waters et al., 2007) pCDNA4-hPdcd4-mutRBM1 þ 2 encodes a mutant Pdcd4 protein with amino-acid substitutions of several basic amino acids in the N-terminal part of Pdcd4 (Wedeken et al., 2010) . Bacterial expression vectors for GST-Pdcd4 and GST-Pdcd4 mutRBM1 þ 2 have been described (Wedeken et al., 2010) .
Antibodies
Western blotting of chicken and human c-Myb was performed with Myb-specific monoclonal antibodies 5E11 (Sleeman, 1993) and myb 2-37 (Evan et al., 1984) . C/EBPb was detected with a rabbit antiserum raised against full-length chicken C/EBPb (Mink et al., 1996) . Pdcd4 was detected with a rabbit antiserum raised against the N-terminus of human Pdcd4 (Bitomsky et al., 2008) or with a commercial antibody against the C-terminus of Pdcd4 (Upstate Biomol, Hamburg, Germany). Antibodies against GFP were obtained from Roche Diagnostics (Mannheim, Germany).
Nuclear/cytoplasmic fractionation Cells were lysed in hypotonic buffer (10 mM Hepes, pH 7.5; 5 mM KCl; 2 mM MgCl 2 ; 0.5% NP40; 1 mM phenylmethanesulfonylfluoride supplemented with with RNase inhibitor RNaseOUT (Invitrogen) and a protease inhibitor cocktail of pepstatin A, leupeptin hemisulfate and aprotinin) and pelleted at 10 000 r.p.m. for 10 min at 41 C. RNA prepared from the supernatant (cytoplasmic fraction) and the pellet (nuclear fraction) was analyzed by northern blotting as described (Bitomsky et al., 2008) .
Sucrose density gradients
Density gradient centrifugation was performed as described (Wedeken et al., 2010) . Ribosomal RNAs were visualized by agarose gel electrophoresis. For real-time PCR analysis, gradient fractions were treated with proteinase K, and RNA was isolated by ribozol-OLS (Omni Life Sciences, Hamburg, Germany) extraction and ethanol precipitation. cDNA synthesis and real-time PCR were performed as described for RIP.
RNA immunoprecipitation
Approximately 6 Â 10 5 QT6 cells or 10 8 DT40 cells were fixed with 0.5% formaldehyde in growth medium for 10 min at Translation suppression by Pdcd4 P Singh et al room temperature, followed by addition of 125 mM glycine for 5 min. Cells were lysed in hypotonic buffer. Approximately 10% of the supernatant (cytoplasmic fraction) was saved as input sample and the remainder was used for IP for 12 h at 4 1C, using a commercial Pdcd4 antiserum (Upstate), in case of DT40 cells, or rabbit antiserum raised against the N-terminus of human Pdcd4 (Bitomsky et al., 2008) , in case of transiently transfected cells. Immunoprecipitates were collected on protein-A sepharose for 2 h at 4 1C and washed several times with RIPA buffer (10 mM Hepes, pH 7.5; 50 mM NaCl; 0.5% NP40; 0.1% SDS; 0.5% sodium deoxycholate; 1 mM phenylmethanesulfonylfluoride; supplemented with protease cocktail and RNase inhibitor). After elution from the beads with 1% SDS, samples were reverse crosslinked for 4 h at 65 1C and further treated with RNase-free DNase I for 15 min at 371 C, followed by proteinase K treatment for 1 h at 421 C. RNA was purified by ribozol-OLS (Omni Life Sciences) extraction and ethanol precipitation. First-strand cDNA synthesis was performed with a cDNA kit (Fermentas, St. Leon Roth, Germany). Electrophoretic mobility shift assay Subregions from the central part of the c-myb corresponding to nucleotides 660-822 (c-myb #1), 740-949 (c-myb #2) and 714-880 (c-myb #3) of the coding region were amplified by PCR using primers with flanking HindIII and BamHI sites and cloned into the polylinker of pCDNA3. RNAs were transcribed from BamHI-digested template DNA in a volume of 20 ml, using 1 mg template DNA, 1 Â T7 buffer (Invitrogen), 40 U/ml RNaseOUT (Invitrogen), 4 mM rNTPs, 8 mM MgCl 2 , 25 mCi a 32 P-UTP (3000 Ci/mmol) and 50 U T7 RNA polymerase (Invitrogen) for 1 h at 37 1C. An additional RNA (c-myb 1-111) corresponding to nucleotides 1-111 of the c-mybcoding region was transcribed from pCDNA3-chc-myb (containing the full-length c-myb-coding region) and digested with AvrII. The RNA was extracted with TriZOL, ethanolprecipitated and dissolved in diethylpyrocarbonate-treated water. GST-Pdcd4-wt and GST-Pdcd4-mutRBM1 þ 2 have been described (Wedeken et al., 2010) . The proteins were purified by binding to GST sepharose in buffer containing 1 Â phosphate-buffered saline, 1% NP-40, 2 mM DTT, 1 mM phenylmethanesulfonylfluoride and a protease inhibitor cocktail containing pepstatin A, leupeptin and aprotinin. To remove bacterial nucleic acids bound to the protein, the beads were then washed twice with binding buffer containing 300 mM NaCl and 150 mM KCl. Finally, after washing twice with 10 mM Tris-HCl, pH 7.5, the bound protein was eluted in 10 mM Tris-HCl, pH 7.5, supplemented with 15 mM reduced glutathione. The final concentration of GST-Pdcd4 was determined by SDS-PAGE, using known amounts of bovine serum albumin as standard. RNA-binding reactions were set up in 20 ml volume and contained approximately 4 Â 10 6 c.p.m. radioactive RNA, 5 mM Tris-HCl, pH 7.5; 50 mM NaCl, 1 mM EDTA, 2% w/v ficoll and different amounts of bacterially expressed protein. Binding reactions were incubated for 30 min on ice and analyzed by electrophoresis in 5% polyacrylamide (0.5 Â TBE) gels. Gels were dried and analyzed with a phosphor image analyzer (Fuji film, Duesseldorf, Germany).
